GlaxoSmithKline
- Country
- π¬π§United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Efficacy and Safety In Poorly Controlled Type 2 Diabetics
- Conditions
- Diabetes Mellitus, Type 2
- First Posted Date
- 2002-08-30
- Last Posted Date
- 2017-10-09
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 142
- Registration Number
- NCT00044460
GW572016, An Oral Drug For Colorectal Cancer Patients Having Prior Therapy With 5-FU Plus CPT-11 And/Or Oxaliplatin
- Conditions
- Colorectal Cancer
- First Posted Date
- 2002-08-28
- Last Posted Date
- 2014-07-10
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 80
- Registration Number
- NCT00044343
- Locations
- π¨π¦
GSK Clinical Trials Call Center, Sainte-Foy, Quebec, Canada
Pediatric Epilepsy Study in Subjects 1-24 Months
- Conditions
- Epilepsy
- First Posted Date
- 2002-08-26
- Last Posted Date
- 2017-01-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 197
- Registration Number
- NCT00044278
- Locations
- πΉπ·
GSK Investigational Site, Ankara, Turkey
Study to Explore Safety And Tolerability of Fosamprenavir With or Without Ritonavir in Combination With TRIZIVIR or COMBIVIR
- Conditions
- HIV Infections
- First Posted Date
- 2002-08-19
- Last Posted Date
- 2013-02-12
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 60
- Registration Number
- NCT00043888
- Locations
- π¬π§
GSK Clinical Trials Call Center, Manchester, United Kingdom
Extensive Small Cell Lung Cancer Treatment Using An Investigational Drug Plus Chemotherapy In Chemotherapy-Naive Adults
- Conditions
- Small Cell Lung Cancer
- First Posted Date
- 2002-08-16
- Last Posted Date
- 2013-08-21
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 760
- Registration Number
- NCT00043927
- Locations
- π¬π§
GSK Clinical Trials Call Center, Poole, United Kingdom
Measurement Of Serum Levels Of Two Antiepileptic Drugs During Conversion In Patients With Epilepsy
- Conditions
- Epilepsy
- First Posted Date
- 2002-08-16
- Last Posted Date
- 2017-10-09
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 72
- Registration Number
- NCT00043914
Treatment Of Primary Generalized Tonic-Clonic Seizures With An Investigational New Drug
- Conditions
- Epilepsy, Tonic-Clonic
- First Posted Date
- 2002-08-16
- Last Posted Date
- 2017-04-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 141
- Registration Number
- NCT00043901
- Locations
- π΅πͺ
GSK Investigational Site, San Isidro, Lima, Peru
Pediatric Epilepsy Trial in Subjects 1-24 Months
- Conditions
- Epilepsy
- First Posted Date
- 2002-08-15
- Last Posted Date
- 2016-09-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 177
- Registration Number
- NCT00043875
- Locations
- πΉπ·
GSK Investigational Site, Ankara, Turkey
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
- Conditions
- Small Cell Lung CancerLung Cancer, Small Cell
- First Posted Date
- 2002-08-15
- Last Posted Date
- 2017-05-31
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 60
- Registration Number
- NCT00043862
- Locations
- πΊπΈ
GSK Investigational Site, Wausau, Wisconsin, United States
ThromboEmbolism Prevention Efficacy and Safety Trial (TEMPEST)
- First Posted Date
- 2002-07-12
- Last Posted Date
- 2017-05-30
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 343
- Registration Number
- NCT00041509